Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Merck & Cie is currently managing 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is under the review of 1 distinct examiner, KIFLE, BRUCK, who is the busiest examiner with 1 pending action. The prosecution is confined to 1 distinct art unit.
This narrow scope indicates that the company's immediate patent outcome is dependent on 1 official. Practitioners should tailor their responses to the specific technical standards and examination style of this examiner and art unit. The centralized review process allows for a highly efficient and targeted prosecution strategy.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KIFLE, BRUCK | 1 | 79.3% | +15.8% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18799606 | NEW STABLE SALT OF 5,10-METHYLENE-(6R)-TETRAHYDROFOLIC ACID | KIFLE, BRUCK | — |
| Art Unit | Apps |
|---|---|
| 1624 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18799606 | NEW STABLE SALT OF 5,10-METHYLENE-(6R)-TETRAHYDROFOLIC ACID | KIFLE, BRUCK | 1624 | §112Other | Non-Final OA | — | Pending | Aug 09, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMerck & Cie has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Bruck Kifle has the most, with 1 of Merck & Cie's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
